Dear Friends of IAVI,

As I reflect on IAVI’s accomplishments in 2018, I’m pleased to share the significant progress we and our partners made as we continued to work toward an HIV vaccine and applied our strengths to other unmet public health needs. We are more committed than ever to translating scientific discoveries into affordable, accessible public health solutions for the people who need them most.

We advanced an innovative HIV vaccine concept into a Phase I clinical trial known as IAVI G001. The vaccine candidate eOD-GT8 60mer is the first HIV immunogen to be tested in humans that was designed using a structure-based approach based on highly sophisticated and elegant vaccine science. Another promising candidate, BG505 SOSIP.664 gp140, a native-like HIV Envelope trimer, received “safe-to-proceed” designation from the FDA, and screening for a Phase I clinical trial began for volunteer vaccinations in 2019. These vaccine candidates represent an important step forward in the quest to develop an HIV vaccine. If the trial results are encouraging, we may be closer to elucidating the pathway to the production of broadly neutralizing antibodies (bNAbs), proteins that most HIV vaccine researchers think will be a necessary component of immunization against HIV.

In October, IAVI acquired tuberculosis (TB) vaccine clinical research programs and assets, including clinical staff, from Aeras, the product development nonprofit focused on TB vaccines. We have already benefited from the expertise of their TB clinical operations group and South African network. Our organizational expansion closely followed the publication of results from two encouraging TB vaccine efficacy trials to which Aeras was a key contributor. The findings of these trials, if confirmed in follow-up studies, could represent a breakthrough in the decades-long quest to develop an effective TB vaccine. We look forward to working as a team to advance solutions for HIV, TB, and other global health challenges.

Toward our mission of developing affordable, accessible public health solutions, we have successfully built upon our strong work in monoclonal antibodies. We launched an ambitious new initiative to work toward global access to monoclonal antibodies for a range of disease indications, and we established a promising partnership with Serum Institute of India to help achieve this goal. We also signed a memorandum of understanding with the National Institutes of Health to select and advance antibody combinations for HIV prevention and treatment.

We received support from the U.K. Department for International Development to form a consortium to develop monoclonal antibodies to reduce deaths and injury from snakebite envenoming in Africa and India. Additionally, in August 2018, IAVI signed an agreement with CEPI to use our promising vesicular stomatitis virus (VSV) vector platform to advance a vaccine candidate against Lassa fever, a viral hemorrhagic fever illness with a high case-fatality rate.

With the generous support of USAID and other donors, we have continued to cultivate HIV and TB research and development by and with African scientists, with support from scientists in India. In 2018, through the ADVANCE (Accelerate the Development of Vaccines and New Technologies to Combat the AIDS Epidemic) program, researchers provided clinical support for IAVI G001 and contributed to the advancement of several other innovative HIV vaccine candidates toward efficacy trials. The Serum Institute of India partnership will give ADVANCE researchers a unique opportunity to take the most promising bNAbs from bench to field for clinical evaluation. Many of our labs and clinical research center partners are expanding their research capacity so that they can lead humoral immune response evaluation in clinical trials. Moreover, the recently launched online IAVI DataSpace will offer researchers all over the world access to more than 150,000 samples and integrated data from at-risk populations at the center of the epidemic in Africa.

Our achievements rely on the support of our donors, staff, partners, and committed colleagues in global health. We are grateful for your contributions and your passion for solving the world’s most urgent public health challenges, and we look forward to making more progress in 2019.

Best regards,

Mark Feinberg, M.D., Ph.D.
President and CEO
About IAVI

IAVI is a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges including HIV and tuberculosis. Our mission is to translate scientific discoveries into affordable, globally accessible public health solutions.

Through scientific and clinical research in Africa, India, Europe, and the U.S., IAVI is pioneering the development of biomedical innovations designed for broad global access. We develop vaccines and antibodies in and for the developing world and seek to accelerate their introduction in low-income countries.

IAVI programs and partnerships are grounded in the regions of the world where the disease burden is the greatest, and our approach emphasizes sustainability. Our network of clinical research center partners in Africa and India helps strengthen in-country research capacity and supports the training and education of the next generation of scientists. The global impact of our science includes fundamental contributions to understanding the biology of HIV infection, which IAVI and others are applying toward advancing vaccine science and immunology.

IAVI accelerates scientific discovery and development by fostering unique collaborations among academia, industry, local communities, governments, and funders to explore new and better ways to address public health threats that disproportionately affect people living in poverty.

Our global reach, including a clinical research network in five countries in sub-Saharan Africa and in India, has allowed us to make fundamental contributions to understanding the epidemiology, transmission, virology, and immunology of HIV. This work played a key role in facilitating the design of promising HIV vaccine candidates, as well as the discovery of broadly neutralizing antibodies that are now being advanced as promising approaches for HIV prevention. Our integrated capabilities in vaccine and antibody discovery, development, and clinical research take advantage of biopharmaceutical industry expertise to accelerate the development and testing of prevention methods for HIV and other diseases. Through the Product Development Center, we support external researchers with technical and scientific expertise to accelerate the development of their own products.

Our mission

To translate scientific discoveries into affordable, globally accessible public health solutions

Translation science into global health impact
IAVI, in collaboration with partners in the public, private, and philanthropic sectors, develops vaccines and antibodies to address urgent, unmet global health challenges including HIV and tuberculosis. IAVI and its partners conduct and support preclinical work and clinical trials for vaccine and antibody candidates, as well as a long-acting antiretroviral for HIV prevention. Below is the pipeline as of June 2019. For the most updated version, go to www.iavi.org/our-science/pipeline.

### 2019 pipeline

<table>
<thead>
<tr>
<th>Candidates designed to induce broadly neutralizing antibodies</th>
<th>Preclinical</th>
<th>Early clinical trials</th>
<th>Efficacy trials</th>
</tr>
</thead>
<tbody>
<tr>
<td>BG505 GT1.1 gp140/AS01a†</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>mRNA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>eOD-GT8 60mer/AS01a†</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BG505 SOSIP.664 gp140/AS01a†</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Replicating viral vector-based candidates</th>
<th>Preclinical</th>
<th>Early clinical trials</th>
<th>Efficacy trials</th>
</tr>
</thead>
<tbody>
<tr>
<td>VSVΔG-Env.BG505</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VSVΔG-Lassa</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Other vaccine approaches</th>
<th>Preclinical</th>
<th>Early clinical trials</th>
<th>Efficacy trials</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ad26.Mos.HIV/gp140 and Ad26.Mos4.HIV/gp140*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HIVconsv*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PrEPVacc*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ad26.Mos4.HIV/gp140*</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Alternative approaches to deliver bNAb/immunoprophylaxis</th>
<th>Preclinical</th>
<th>Early clinical trials</th>
<th>Efficacy trials</th>
</tr>
</thead>
<tbody>
<tr>
<td>Enhanced bNAb for HIV prevention</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>bNAb PG121, PGDM1400, and/or VRC07 523LS*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>bNAb 38NC117 and 10-1074*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>bNAb PG121, VRC07-523LS, and PGDM1400*</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Long-acting antiretrovirals</th>
<th>Preclinical</th>
<th>Early clinical trials</th>
<th>Efficacy trials</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cabotegravir*</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Tuberculosis (TB) vaccine candidates</th>
<th>Preclinical</th>
<th>Early clinical trials</th>
<th>Efficacy trials</th>
</tr>
</thead>
<tbody>
<tr>
<td>MTBVAC*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M72/AS01.e**</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>H56/IC31*</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*† Includes third party candidates under development where IAVI is providing translational and/or clinical development support.
† The GSK proprietary AS01 adjuvant system contains QS-21 Stimulon® adjuvant licensed from Antigenics LLC, a wholly owned subsidiary of Agenus Inc. (NASDAQ: AGEN), MPL and liposomes.
Our track record

Accelerate vaccine research with a pipeline of novel vaccine approaches and the development of new tools and technologies

- 33 HIV vaccine candidates advanced to clinical trials across 11 countries; with first ever Phase I trials in Kenya, Rwanda, Zambia, India and Germany
- 47 Epidemiology studies conducted that informed the design of HIV vaccine efficacy trials; improving future accessibility and acceptability of final product
- 81 Potent and broad HIV neutralizing antibodies identified and used in research for vaccine design and other prevention and treatment modalities. Since 2009, 2,200 samples have been collected from people living with HIV, bringing new hope for a protective HIV vaccine; 3 of IAVI’s isolated antibodies being used in clinical studies
- 3 IAVI-sponsored replicating viral vector candidates advanced in novel portfolio toward clinical development
- 1 million Vaccine trial and epidemiology samples collected and stored, maximizing scientific advances by sharing all of these materials, promising technologies and technical expertise

Strengthen a new model of African scientific collaboration for vaccine research and development and future access

- 11 State-of-the-art partner network CRCs in Africa and India with 12 GCLP-accredited laboratories capable of conducting clinical research at international standards
- 500+ Scientists in the developing world trained in Good Clinical Practices and GCLP to international standards for conducting clinical trials
- 90% Overall retention rate of HIV vaccine trial participants with an average of 44% participation by females; bringing better gender balance to trial data for more accurate vaccine design
- 107 Community workers and health workers trained on integrating gender issues into HIV vaccine clinical research, based on IAVI’s past experience and training manuals developed
- 20 Early stage scientists supported with research grants
- 31 Advanced degree candidates supported by ITP; 15 students ongoing; 8 PhD/23 MSc; 10 adolescent research fellowships

Work in partnership for continued support for AIDS vaccine research and development

- 100+ Partners from academia, biotechnology, and pharmaceutical sector, as well as civil society and global health initiatives
- 25+ Governments, foundations and other donors; with work in 22 countries over 4 regions
- 35 Projects managed by the Vaccine Product Development Center since its establishment in 2013, as an integrated platform to advance promising concepts from bench to clinic; 20 external investigators supported to date
- 20 Phase I/II trials supported by IAVI’s Product Development Center assessing external vaccine candidates and biologicals
- 15 Biotechnology partners engaged in HIV vaccine research and development through the Innovation Fund, yielding new technologies such as advanced screening tools, a manufacturing platform, and novel vaccine delivery

Provide benefits for communities

- 790,000+ People in Africa received counseling services and health care referrals for treatment and care
- 8 National and regional policies included HIV vaccine research, resulting in enhanced local ownership and an improved environment for research with at-risk populations
- 900 Volunteers enrolled in IAVI-sponsored HIV vaccine trials in Africa; more than 48,000 participants enrolled into epidemiology studies that not only helped HIV research, but also informed about other problems and health care issues relevant for each respective community

Our track record

IAVI | 2018 Annual Report
## 2018 financials

All figures in millions of U.S. dollars

### REVENUE

#### Grants and contributions

<table>
<thead>
<tr>
<th>Source</th>
<th>2017</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Governments</td>
<td>39.5</td>
<td>43.3</td>
</tr>
<tr>
<td>Foundations</td>
<td>42.7</td>
<td>35.5</td>
</tr>
<tr>
<td>Investment income and other</td>
<td>0.7</td>
<td>1.2</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>82.9</strong></td>
<td><strong>80.0</strong></td>
</tr>
</tbody>
</table>

### EXPENSES

#### Programs

<table>
<thead>
<tr>
<th>Category</th>
<th>2017</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research and development</td>
<td>54.2</td>
<td>60.6</td>
</tr>
<tr>
<td>Contract manufacturing-related activities</td>
<td>19.0</td>
<td>10.1</td>
</tr>
<tr>
<td>Vaccine advocacy, public affairs, and policy</td>
<td>2.6</td>
<td>2.8</td>
</tr>
<tr>
<td>Administration</td>
<td>8.0</td>
<td>8.5</td>
</tr>
<tr>
<td>Fundraising</td>
<td>1.7</td>
<td>1.7</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>85.5</strong></td>
<td><strong>83.7</strong></td>
</tr>
</tbody>
</table>

### ASSETS

<table>
<thead>
<tr>
<th>Category</th>
<th>2017</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and investments</td>
<td>55.1</td>
<td>60.2</td>
</tr>
<tr>
<td>Grants receivables</td>
<td>19.4</td>
<td>21.3</td>
</tr>
<tr>
<td>Fixed assets</td>
<td>7.6</td>
<td>6.5</td>
</tr>
<tr>
<td>Other</td>
<td>0.5</td>
<td>0.4</td>
</tr>
<tr>
<td><strong>Total Assets</strong></td>
<td><strong>82.6</strong></td>
<td><strong>88.4</strong></td>
</tr>
</tbody>
</table>

### Liabilities

<table>
<thead>
<tr>
<th>Category</th>
<th>2017</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liabilities</td>
<td>38.2</td>
<td>46.4</td>
</tr>
<tr>
<td><strong>Net assets</strong></td>
<td><strong>44.4</strong></td>
<td><strong>42.0</strong></td>
</tr>
<tr>
<td><strong>Total liabilities and net assets</strong></td>
<td><strong>82.6</strong></td>
<td><strong>88.4</strong></td>
</tr>
</tbody>
</table>
Board of Directors

Linda-Gail Bekker
Deputy Director
Desmond Tutu HIV Centre
Immediate Past President
International AIDS Society

David L. Blumberg
Vice President, Teva Global Operations and Portfolio Compliance
Teva Pharmaceuticals

Jim Connolly
Former President and CEO
Aeras

The Hon. Mark Dybul, M.D.
Faculty Co-director of the Center for Global Health Quality and Professor in the Department of Medicine
Georgetown University Medical Center

Mark B. Feinberg, M.D., Ph.D.
President and CEO
International AIDS Vaccine Initiative

Robert Goldberg, M.A. (Treasurer)
Chief Operating Officer
Barnard College

Eric Paul Goosby, M.D. (Chair)
Director
Center for Implementation Sciences
Global Health Sciences
University of California, San Francisco

Purnima Mane, Ph.D., M.A., M.Phil.
Former President and CEO
Pathfinder International

John Nkengasong, Ph.D.
Director
Africa Centres for Disease Control and Prevention

Francine Ntoumi, Ph.D., HDR, FRCP (Edin.)
Research Group Leader
Institute for Tropical Medicine
University of Tübingen

John Shiver
Senior Vice President of Global Vaccine R&D
Sanofi Pasteur

Anne Simonds
Board/CEO Leadership Adviser, Global Leader of Health, Development and Social Enterprise
Spencer Stuart

Anne M. VanLent (Vice Chair)
President
AMV Advisors

Rajeev Venkayya, M.D.
President, Global Vaccine Business Unit
Takeda Pharmaceuticals

Marijke Wijnroks
Chief of Staff
The Global Fund to Fight AIDS, Tuberculosis and Malaria
Thank you to all of our generous donors, whose support makes possible the advancement of research and clinical trials toward affordable, globally accessible public health solutions.

IAVI gratefully acknowledges the generous support provided by the following major donors:

- USAID
- PEPFAR
- Bill & Melinda Gates Foundation
- The World Bank
- CEPI
- UK aid
- EDCTP
- JAPAN
- Ministry of Foreign Affairs of Denmark
- The Research Council of Norway
- Ministry of Foreign Affairs of the Netherlands
- Irish Aid
- Ministry of Foreign Affairs of Denmark
- Ministry of Foreign Affairs of the Netherlands
- Ministry of Science & Technology, Government of India
- National Institute of Allergy and Infectious Diseases
- The Research Council of Norway
- The World Bank
- Department for International Development
- The U.S. President’s Emergency Plan for AIDS Relief through the U.S. Agency for International Development
- Danida

And many other generous individuals and partners around the world.

As of August 2019